CN113142586A - 一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 - Google Patents
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 Download PDFInfo
- Publication number
- CN113142586A CN113142586A CN202110374963.8A CN202110374963A CN113142586A CN 113142586 A CN113142586 A CN 113142586A CN 202110374963 A CN202110374963 A CN 202110374963A CN 113142586 A CN113142586 A CN 113142586A
- Authority
- CN
- China
- Prior art keywords
- composite
- helicobacter pylori
- inhibiting
- hundred million
- gastric mucosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 66
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 66
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 35
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 34
- 210000001156 gastric mucosa Anatomy 0.000 title claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 title claims description 20
- 150000001875 compounds Chemical class 0.000 title abstract description 13
- 230000000529 probiotic effect Effects 0.000 claims abstract description 43
- 239000002131 composite material Substances 0.000 claims abstract description 37
- 239000013589 supplement Substances 0.000 claims abstract description 35
- 241000894006 Bacteria Species 0.000 claims abstract description 30
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 27
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 26
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 26
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 26
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 26
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 20
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 19
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 19
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 16
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 16
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 15
- 230000008676 import Effects 0.000 claims description 19
- 241000186000 Bifidobacterium Species 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940068140 lactobacillus bifidus Drugs 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 20
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 abstract description 11
- 229940009289 bifidobacterium lactis Drugs 0.000 abstract description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 11
- 241001134770 Bifidobacterium animalis Species 0.000 abstract description 10
- 229940118852 bifidobacterium animalis Drugs 0.000 abstract description 10
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 230000006378 damage Effects 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 206010019375 Helicobacter infections Diseases 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002368 bacteriocinic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及益生菌补充剂技术领域；尤其涉及一种可以有效抑制及杀灭幽门螺杆菌的益生菌补充剂，并添加L‑谷氨酰胺颗粒辅助修复受损伤的胃黏膜(包括肠粘膜)；该复合补充剂单位剂量包含益生菌：罗伊氏乳杆菌、嗜酸乳杆菌、乳双歧杆菌、动物双岐杆菌、鼠李糖乳杆菌；同时包含L‑谷氨酰胺颗粒、水苏糖、低聚果糖。该复合益生菌能够有效改善胃肠道内菌群环境，修复胃肠黏膜损伤；同时有利于胃肠内有益菌菌株增殖，并且该复合益生菌具有更好的口感。
Description
技术领域
本发明涉及益生菌补充剂技术领域，尤其涉及一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌
背景技术
由于现今城市化建设加快，人口密集程度提高，同时由于水体污染，导致环境中的幽门螺杆菌含量上升，加大了人们感染幽门螺杆菌的可能，全球幽门螺杆菌的感染率超过50％。“口口”相传为幽门螺杆菌传染的主要方式，在中国传统生活习俗(大锅饭，大桌菜且很少分餐)的影响下，人们更容易感染幽门螺杆菌。幽门螺杆菌被认为是导致胃溃疡及胃癌的重要因素。以往的抗幽门螺杆菌治疗常用多种抗生素联用的方案；该方案需长期使用抗生素治疗(常常达数月之久)，具有伤胃伤肝伤肾的缺点，而且疗效也并不理想，经常反复。而复合益生菌产品具有改善胃肠道环境，调节人体菌群平衡，抗过敏，促进消化等功能，且无任毒副作用，使用安全，可以说是一种集治胃、养胃、保肝、保肾于一体的绿色治疗产品。感染幽门螺杆菌使肠道内菌群失衡，有害菌过度繁殖。益生菌能通过粘附幽门螺杆菌；产生生物素、有机酸等抑菌物质；改变肠道内菌群生存环境；竞争食物等多种机制抑制其生存并最后杀灭之。使用益生菌治疗是一种快速有效、无毒无害的治疗方法。
多种益生菌联合使用可以有效解决以往药物治疗中的根治率低且伤肝伤肾伤胃的弊端。本产品中所包含的罗伊氏乳杆菌具有粘附幽门螺杆菌并使之脱离胃肠道表面的作用，嗜酸乳杆菌具有分泌生物素的直接作用，乳双歧杆菌、动物双岐杆菌、鼠李糖乳杆菌的协同作用使得肠道的环境更适合有益菌的生存从而抑制/杀灭有害菌。同时本产品中所包含的L-谷氨酰胺颗粒修复胃黏膜损伤，改善胃肠功能。因此本产品具有一“药”多能、无副作用的特点。
发明内容
本发明的目的是解决现代医学中胃幽门螺杆菌感染易复发、不易治愈、人群发病率高、易并发胃溃疡胃癌等严重后果等诸多问题；用一种多益生菌的复合补充剂协同作用抑制且彻底清除幽门螺杆菌感染同时修复感染后胃黏膜损伤。
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌50-400亿(包括进口)、嗜酸乳杆菌50 -400亿(包括进口)、乳双歧杆菌25-100亿(包括进口)、动物双歧杆菌25- 100亿个鼠李糖乳杆菌25-100亿(包括进口)；还包括L-谷氨酰胺颗粒0- 3g；及水苏糖、低聚果糖等；
益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在175亿-1000亿之间。
优选的，所述复合益生菌中含有L-谷氨酰胺0-3g。
优选的，所述复合益生菌中含有水苏糖、低聚果糖，添加量为其重量的2-5％。
优选的，所述复合益生菌中单位剂量中包含：活性罗伊氏乳杆菌200 亿个(包括进口)、活性嗜酸乳杆菌200亿个(包括进口)、活性乳双岐杆菌 100亿个(包括进口)、活性动物双岐杆菌50亿个(包括进口)、活性鼠李糖乳杆菌50亿个(包括进口)。
本发明的有益效果是：
本发明通过5种益生菌的协同作用：分别为粘附-生物素类直接作用-竞争食物及产生有益于益生菌生存环境从而在不损伤胃、肝、肾时抑制并最终杀灭幽门螺杆菌；通过L-谷氨酰胺修复胃黏膜损伤，改善症状；一种复合益生菌添加剂可以起到多种作用：养胃-护胃-杀菌-根治。
本品含有罗伊氏乳杆菌，罗伊氏乳杆菌对肠黏膜具有很强的黏附能力，可改善肠道菌群分布，拮抗有害菌定植，避免罹患肠道疾病；由于罗伊氏乳杆菌与幽门螺杆菌表面结构的契合度非常高，一旦相遇，它们就不会再分开；所以在体内/胃内罗伊氏乳杆菌总能快速找到幽门螺杆菌并且可以“像钩子一样钩住它”，然后罗伊氏乳杆菌能产生一种被称为“罗伊氏菌素”的非蛋白质类广谱抗菌物质，能广泛抑制幽门螺杆菌及革兰氏阳性菌、革兰氏阴性菌、酵母、真菌和病原虫等的生长。罗伊氏乳杆菌益生菌制剂可改善人体机能，提高免疫力从而促进人体健康。
本品含有嗜酸乳杆菌，嗜酸乳杆菌对致病微生物具有拮抗作用。嗜酸乳杆菌能分泌抗生物素类物质(嗜酸乳菌素、嗜酸杆菌素、乳酸菌素)，对幽门螺杆菌等胃肠道致病菌产生拮抗作用。
本品含有乳双歧杆菌；双歧杆菌具有调节肠道菌群的作用；可以有效的缓解便秘；可以产生乙酸、乳酸，来抑制肠道腐败菌的生长和有毒代谢产物的形成；双歧杆菌还能保肝脏，双歧杆菌可以促进人体对乳糖的消化，从而缓解因为乳糖不耐受而引起的肠痉挛、肠胀气以及腹泻的症状，乳双歧杆菌的加入使得肠道内环境更有利于包括罗伊氏乳杆菌和嗜酸乳杆菌在内的益生菌得以更好的生存和繁殖。
本品含有动物双歧杆菌，参与免疫、营养、消化和保护等一系列的生理过程，发挥着重要的功能。抑制腐败菌生长，动物双歧杆菌可迅速在肠粘膜定植，形成有益菌屏障，密布于肠粘膜上形成菌膜，使致病菌包括幽门螺杆菌无法定植。动物双歧杆菌产生的醋酸、乳酸使肠道pH值降低，达到抑制腐生菌的目的。动物双歧杆菌产生似细菌素的蛋白质，有一定的杀菌作用。动物双歧杆菌可使偶联型胆汁酸分解为游离型胆汁酸，该种酸对细菌抑制作用更强。
本品含有鼠李糖乳杆菌，耐酸、耐胆汁盐、耐多种抗生素等；鼠李糖乳杆菌是肠道正常的菌群之一，它是一种定植菌，由于它的定植作用可以抑制有害菌包括幽门螺杆菌的生长，从而促进有益菌。比如双歧杆菌的作用和生长，从而调节肠道正常的菌群环境，这样子就可以抑制疾病的发生，同时鼠李糖乳杆菌还有增加机体免疫力的作用，对于缓解过敏也有一定的帮助，比如增加了机体的免疫力，对湿疹的缓解也有一定的帮助。
L-谷氨酰胺颗粒的加入：L-谷氨酰胺为氨基酸类，对胃肠黏膜损伤具有保护和修复作用，其原因为谷氨酰胺对胃肠黏膜上皮成分，己糖胺及葡萄糖胺的生化合成有促进作用。并且有利于肠道吸收功能和机体免疫功能的恢复。
水苏糖、低聚果糖的加入：水苏糖和低聚果糖均是重要的益生元，加入有利于复合益生菌中益生菌的生存；同时水苏糖具有活性因子，可吸附胃肠道有毒物质及病原菌，提高机体抗病力，增强免疫能力能促进人体对钙、镁的吸收；低聚果糖拥有低热值、降血糖，改善血清脂质，促进微量元素吸收等优良生理功能，并且可以促进双歧杆菌等有益益生菌的增殖，在酸性条件下也具有稳定的化学结构。水苏糖和低聚果糖是重要的调味剂，可以使得产品带有低度的甜味，改善口感。
具体实施方式
下面结合具体实施例对本发明做进一步解说。
实施例一：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌200亿(包括进口)、嗜酸乳杆菌200亿 (包括进口)、动物双歧杆菌50亿个(包括进口)、乳双歧杆菌100亿(包括进口)、鼠李糖乳杆菌50亿(包括进口)；还包括L-谷氨酰胺颗粒2g；及水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在600亿个，同时该复合益生菌补充剂中含L-谷氨酰胺颗粒2g；及水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例二：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌100亿(包括进口)、嗜酸乳杆菌100 亿(包括进口)、动物双歧杆菌25亿个(包括进口)、乳双歧杆菌50亿(包括进口)、鼠李糖乳杆菌25亿(包括进口)；还包括L-谷氨酰胺颗粒1g；及水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在300亿个，同时该复合益生菌补充剂中含L-谷氨酰胺颗粒1g；及水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例三：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌200亿(包括进口)、嗜酸乳杆菌200 亿(包括进口)、动物双歧杆菌50亿个(包括进口)、乳双歧杆菌100亿(包括进口)、鼠李糖乳杆菌50亿(包括进口)；不包括L-谷氨酰胺颗粒；及水苏糖、低聚果糖等；本方案不加L-谷氨酰胺；只杀幽门螺杆菌，不加入保护胃黏膜成分；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在600亿个，同时该复合益生菌补充剂中不含L-谷氨酰胺颗粒；及水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例四：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌200亿(包括进口)、嗜酸乳杆菌200 亿(包括进口)、动物双歧杆菌50亿个(包括进口)、乳双歧杆菌100亿(包括进口)、鼠李糖乳杆菌50亿(包括进口)；不包括L-谷氨酰胺颗粒；含水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在300亿个，同时该复合益生菌补充剂中不含L-谷氨酰胺颗粒；含水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例五：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌400亿(包括进口)、嗜酸乳杆菌400亿 (包括进口)、动物双歧杆菌50亿个(包括进口)、乳双歧杆菌100亿(包括进口)、鼠李糖乳杆菌50亿(包括进口)；还包括L-谷氨酰胺颗粒3g；及水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在1000亿个，同时该复合益生菌补充剂中含L-谷氨酰胺颗粒 3g；及水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例六：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌400亿(包括进口)、嗜酸乳杆菌400亿 (包括进口)、动物双歧杆菌50亿个(包括进口)、乳双歧杆菌100亿(包括进口)、鼠李糖乳杆菌50亿(包括进口)；不包括L-谷氨酰胺颗粒；包括水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在1000亿个，同时该复合益生菌补充剂中不包含L-谷氨酰胺颗粒；含水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例七：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌400亿(包括进口)、嗜酸乳杆菌400亿 (包括进口)；还包括L-谷氨酰胺颗粒2g；及水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在800亿个，同时该复合益生菌补充剂中含L-谷氨酰胺颗粒2g；及水苏糖、低聚果糖等，重量为其整个重量的3.5％。
实施例八：
一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌补充剂，所述益生菌补充剂单位剂量中包含罗伊氏乳杆菌400亿(包括进口)、嗜酸乳杆菌400亿 (包括进口)；及水苏糖、低聚果糖等；
本实施例中益生菌复合补充剂的制作流程为：
优选的，所述活性有益菌成分在800亿个，及水苏糖、低聚果糖等，重量为其整个重量的 3.5％。
需要说明的是，本专利申报中，所列出的益生菌、L-谷氨酰胺颗粒、益生元产品等及较多的实施例，不仅包括实施例中所包括的量，对于本领域的技术人员而言，可以理解在不脱离本发明的原理的基础上，对这些实例进行多种变化、修改、替换和变型；本发明的范围由所附权利要求及其等同物限定。
Claims (6)
1.一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，其特征在于，每包主要成分除了包括：罗伊氏乳杆菌50-400亿(包括进口)、嗜酸乳杆菌50-400亿(包括进口)、动物双歧杆菌25-100亿个(包括进口)、乳双歧杆菌25-100亿(包括进口)、鼠李糖乳杆菌25-100亿(包括进口)；还包括L-谷氨酰胺颗粒0-3g；及水苏糖、低聚果糖等。
2.根据权利要求1所述的一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，其特征在于，益生菌复合补充剂的制作流程为：
3.根据权利要求1所述的一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，其特征在于，所述益生菌活菌成分总量单位剂量在175-1100亿个活菌之间。
4.根据权利要求1所述的一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，其特征在于单位剂量中加入L-谷氨酰胺颗粒0-3g。
5.根据权利要求1所述的一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，其特征在于复合补充剂中还包括水苏糖、低聚果糖；添加量为复合益生菌的重量的2-5％。
6.根据权利要求1所述的一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌，其特征在于，所述益生菌复合补充剂单位剂量包含：活性罗伊氏乳杆菌200亿个(包括进口)、活性嗜酸乳杆菌200亿个(包括进口)、活性乳双岐杆菌100亿个(包括进口)、活性动物双岐杆菌50亿个(包括进口)、活性鼠李糖乳杆菌50亿个(包括进口)。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110374963.8A CN113142586A (zh) | 2021-04-02 | 2021-04-02 | 一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110374963.8A CN113142586A (zh) | 2021-04-02 | 2021-04-02 | 一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113142586A true CN113142586A (zh) | 2021-07-23 |
Family
ID=76889248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110374963.8A Pending CN113142586A (zh) | 2021-04-02 | 2021-04-02 | 一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113142586A (zh) |
-
2021
- 2021-04-02 CN CN202110374963.8A patent/CN113142586A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11878040B2 (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| CA2748200C (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| RU2731148C2 (ru) | Композиция для применения в профилактике или лечении инфекций/воспалений в желудочно-кишечном тракте у младенцев или детей младшего возраста | |
| EP1596872B1 (en) | Compositions and methods for restoring bacterial flora | |
| EP1262192A2 (en) | Compositions and methods for human gastrointestinal health | |
| Franceschi et al. | Role of probiotics in patients with Helicobacter pylori infection | |
| US20070286916A1 (en) | Synbiotic Use | |
| RU2445361C2 (ru) | Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий | |
| JP2010535731A (ja) | ラクトバチルスラムノサス及び体重管理 | |
| KR101000364B1 (ko) | 생존율 증강용 이중 코팅 방법 | |
| US8304226B2 (en) | Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine | |
| CN113142586A (zh) | 一种可抑制杀灭幽门螺杆菌、修复胃黏膜的复合益生菌 | |
| CN114642262A (zh) | 抗幽益生菌组合物及其制品和制造方法 | |
| AU2013205352A1 (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| AU2016203744A1 (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| Osman et al. | Probiotic strains of Lactobacillus and Bifidobacterium affect the translocation and intestinal load of Enterobacteriaceae differently after D-galactosamine-induced liver injury in rats | |
| CN115737688A (zh) | 一种可抑制杀灭幽门螺旋杆菌的益生菌产品 | |
| CN114468305B (zh) | 一种缓解过度运动引起的不良反应的益生菌组合物及应用 | |
| Al-Qayim et al. | Effects of probiotics (Lactobacillus acidophilus) on some intestinal physiological aspects in experimental colitis in rats | |
| CN111743998A (zh) | 用于辅助治疗肠炎组合物及其制备方法 | |
| TW201029657A (en) | Probiotics fermentation composition capable of inhibiting activity of salmonella | |
| PL220647B1 (pl) | Preparat probiotyczny i zastosowanie preparatu probiotycznego |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |